Skip to main content

Table 1 Demographics, baseline characteristics and medical history of patients enrolled in the ERICA trial[4]

From: Impact of angina frequency on health utility values of patients with chronic stable angina

Characteristics Placebo + Amlodipine (n = 283) Ranolazine + Amlodipine (n = 281)
Age (years), mean ± SD 61.3 ± 9.0 62.0 ± 8.7
Gender (M/W),% 73/27 72/28
Race,%   
White 99 98
Black 1 1
Asian 0 <1
Geographic region,%   
Eastern Europe 97 97
North America 3 3
Concomitant use of LANs,% 43 46
Weekly rate of angina attacks,trimmed mean ± SE 5.68 ± 0.26 (n = 281) 5.59 ± 0.21 (n = 277)
Weekly rate of NTG consumption, trimmed mean ± SE 5.02 ± 0.33 (n = 281) 4.43 ± 0.26 (n = 277)
SAQ score, mean ± SD   
Angina frequency 40.0 ± 14.9 (n = 281) 40.6 ± 13.2 (n = 277)
Physical limitation 48.9 ± 17.3 (n = 276) 49.2 ± 17.4 (n = 271)
Anginal stability 57.2 ± 17.7 (n = 281) 54.7 ± 18.0 (n = 277)
Disease perception 41.5 ± 17.8 (n = 281) 41.6 ± 17.2 (n = 277)
Treatment satisfaction 75.4 ± 14.0 (n = 281) 74.6 ± 14.3 (n = 277)
History of unstable angina,% 98 (35) 100 (36)
History of CHF,% 145 (51) 146 (52)
NYHA functional class I 38 (13) 32 (11)
NYHA functional class II 86 (30) 99 (35)
NYHA functional class III 21 (7) 15 (5)
NYHA functional class IV 0 0
Diabetes mellitus,% 54 (19) 52 (19)
Insulin-dependent 2 (1) 11 (4)
Previous myocardial infarction,% 233 (82) 218 (78)
Previous CABG,% 34 (12) 28 (10)
Previous PCI 25 (9) 34 (12)
Intermittent claudication,% 32 (11) 39 (14)
Hypertension,% 257 (91) 246 (88)
  1. CABG = Coronary Artery Bypass Grafting; CHF = Congestive Heart Failure; ERICA = Efficacy of Ranolazine in Chronic Angina; LAN = long-acting nitrate; NTG = nitroglycerin; NYHA = New York Heart Association; PCI = Percutaneous Coronary Intervention; SAQ = Seattle Angina Questionnaire; SD = standard deviation; SE = standard error.